Detalles de la búsqueda
1.
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Hematol Oncol;
40(5): 1009-1019, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35638723
2.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol;
108(3): 178-189, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34716957
3.
Neuroimaging of leptomeningeal myelomatosis: a rare and severe entity.
Ann Hematol;
101(9): 2091-2092, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35525882
4.
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
Front Oncol;
12: 890376, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35924160
5.
Role of parenteral nutrition in cancer patients undergoing high-dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation.
Tumori;
91(3): 237-40, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16206647
Resultados
1 -
5
de 5
1
Próxima >
>>